Company Profile:

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.

Recent News:

The company will release its financial results for the second quarter 2017, on Monday, August 14, 2017. The Company will also hold an earnings call at 5:00 PM Eastern on Monday, August 14, 2017 to discuss the financial results and provide company updates.

For the first quarter 2017, the company reported a loss of $9.6 million. It had a loss of 51 cents per share on revenue of $7 million. Losses, adjusted for non-recurring costs, came to 11 cents per share.

On June 27, 2017, the company announced the launch of Thermo Fisher Scientific’s (Thermo Fisher) Oncomine Dx Target. Approved by the FDA on June 22 of 2017, the Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

CGIX’s strengths can be seen in its strong growth and better efficiency compared with its peers. Its revenue has increased over several years. Technical indicators signal the bullish signs, as there is a bullish cross in Stochastic Oscillator and RSI stands at 44.85 with positive bias. We rate Cancer Genetics, Inc. (CGIX) a STRONG BUY.